Alnylam Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Alnylam Pharmaceuticals Inc 公司

Alnylam Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司。該公司致力於發現、開發、製造和商業化基於核糖核酸干擾 (RNAi) 的新型療法。其上市產品包括用於治療成人遺傳性轉甲狀腺素介導性澱粉樣變性 (hATTR) 伴多發性神經病的 AMVUTTRA (vutrisiran)；用於治療成人 hATTR 澱粉樣變性伴多發性神經病的 ONPATTRO (patisiran)；用於治療成人急性肝卟啉症的 GIVLAARI (givosiran)；用於治療 1 型原發性高草酸尿症的 OXLUMO (lumasiran)，以及由其合作伙伴諾華公司開發和商業化的 Leqvio (inclisiran)，用於治療成人高膽固醇血癥或混合性血脂異常。該公司的臨牀開發項目包括 Cemdisiran、Fitusiran、Zilebesiran、Elebsiran、Mivelsiran 和 ALN-HTT02。該公司正在開發 Cemdisiran 來治療補體介導的疾病。

公司簡介

公司代碼ALNY

公司名稱Alnylam Pharmaceuticals Inc

上市日期May 28, 2004

成立日期2003

CEODr. Yvonne L. Greenstreet, M.D.

員工數量2230

證券類型Ordinary Share

年結日May 28

公司地址675 W Kendall St

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02142-1168

電話16175518200

網址https://www.alnylam.com/

公司代碼ALNY

上市日期May 28, 2004

成立日期2003

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Phillip A. (Phil) Sharp, Ph.D.

Independent Director

266.90K

--

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

99.04K

+16.58%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

47.81K

+40.80%

Mr. Tolga Tanguler

Chief Commercial Officer

28.01K

+95.27%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.03K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

3.64K

--

Dr. Margaret A. Hamburg, M.D.

Independent Director

136.00

--

Ms. Colleen F. Reitan

Independent Director

--

Ms. Amy W. Schulman, J.D.

Independent Chairman of the Board

--

Ms. Carolyn R. Bertozzi, M.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Phillip A. (Phil) Sharp, Ph.D.

Independent Director

266.90K

--

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

99.04K

+16.58%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

47.81K

+40.80%

Mr. Tolga Tanguler

Chief Commercial Officer

28.01K

+95.27%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.03K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

3.64K

--

收入明細

單位: USD更新時間: 4月6日週日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

業務USD

名稱

營收

佔比

AMVUTTRA

970.45M

43.16%

Regeneron Pharmaceuticals

302.80M

13.47%

GIVLAARI

255.87M

11.38%

ONPATTRO

252.86M

11.25%

OXLUMO

167.05M

7.43%

Other

299.22M

13.31%

地區USD

名稱

營收

佔比

United States

933.54M

41.52%

Europe

516.30M

22.96%

Net revenues from collaborations

510.22M

22.69%

Rest of World

196.39M

8.74%

Royalty revenue

91.79M

4.08%

業務

地區

業務USD

名稱

營收

佔比

AMVUTTRA

970.45M

43.16%

Regeneron Pharmaceuticals

302.80M

13.47%

GIVLAARI

255.87M

11.38%

ONPATTRO

252.86M

11.25%

OXLUMO

167.05M

7.43%

Other

299.22M

13.31%

股東統計

更新時間: 2月21日週五

持股股東

股東類型

持股股東

股東統計

佔比

Capital World Investors

12.76%

The Vanguard Group, Inc.

10.04%

Fidelity Management & Research Company LLC

9.95%

Capital Research Global Investors

5.36%

BlackRock Institutional Trust Company, N.A.

5.19%

Other

56.70%

持股股東

股東統計

佔比

Capital World Investors

12.76%

The Vanguard Group, Inc.

10.04%

Fidelity Management & Research Company LLC

9.95%

Capital Research Global Investors

5.36%

BlackRock Institutional Trust Company, N.A.

5.19%

Other

56.70%

股東類型

股東統計

佔比

Investment Advisor

56.07%

Investment Advisor/Hedge Fund

32.20%

Corporation

3.44%

Hedge Fund

2.58%

Sovereign Wealth Fund

1.97%

Pension Fund

1.43%

Bank and Trust

1.19%

Research Firm

1.07%

Individual Investor

0.43%

機構持股

更新時間: 1月19日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

1235

131.13M

100.81%

-458.58K

2024Q4

1263

130.73M

100.99%

-1.47M

2024Q3

1225

126.90M

98.51%

-1.26M

2024Q2

1183

123.30M

96.32%

+1.12M

2024Q1

1172

117.88M

93.23%

-5.46M

2023Q4

1169

120.70M

96.18%

-5.54M

2023Q3

1125

121.55M

96.89%

-6.15M

2023Q2

1119

122.11M

98.30%

-6.32M

2023Q1

1116

123.13M

99.37%

-5.56M

2022Q4

1103

122.98M

99.27%

-3.16M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

16.60M

12.76%

+92.10K

+0.56%

Dec 31, 2024

The Vanguard Group, Inc.

13.06M

10.04%

+378.83K

+2.99%

Mar 31, 2025

Fidelity Management & Research Company LLC

12.94M

9.95%

-1.20M

-8.49%

Dec 31, 2024

Capital Research Global Investors

6.97M

5.36%

+1.72M

+32.89%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

6.75M

5.19%

+149.81K

+2.27%

Dec 31, 2024

Regeneron Pharmaceuticals Inc

4.44M

3.42%

+4.44M

--

Dec 31, 2024

T. Rowe Price Investment Management, Inc.

4.38M

3.37%

+1.25M

+39.67%

Dec 31, 2024

Wellington Management Company, LLP

4.20M

3.23%

-756.72K

-15.28%

Dec 31, 2024

Baillie Gifford & Co.

4.04M

3.11%

-846.74K

-17.33%

Dec 31, 2024

Dodge & Cox

3.54M

2.72%

-82.27K

-2.27%

Dec 31, 2024

持股ETF

更新時間: 4月6日週日

機構名稱

佔比

Tema Neuroscience and Mental Health ETF

4.39%

VanEck Biotech ETF

4.19%

Global X Genomics & Biotechnology ETF

3.91%

ProShares Ultra Nasdaq Biotechnology

3.49%

First Trust NYSE Arca Biotechnology Index Fund

3.23%

iShares Biotechnology ETF

3.11%

Invesco Nasdaq Biotechnology ETF

3.05%

Franklin Genomic Advancements ETF

2.56%

American Century Focused Dynamic Growth ETF

2.52%

SPDR S&P Biotech ETF

2.5%

Tema Neuroscience and Mental Health ETF

佔比4.39%

VanEck Biotech ETF

佔比4.19%

Global X Genomics & Biotechnology ETF

佔比3.91%

ProShares Ultra Nasdaq Biotechnology

佔比3.49%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.23%

iShares Biotechnology ETF

佔比3.11%

Invesco Nasdaq Biotechnology ETF

佔比3.05%

Franklin Genomic Advancements ETF

佔比2.56%

American Century Focused Dynamic Growth ETF

佔比2.52%

SPDR S&P Biotech ETF

佔比2.5%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Alnylam Pharmaceuticals Inc

251.560USD

Alnylam Pharmaceuticals Inc

251.560

概覽

公司